DEPO - Depomed, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
7.44
+0.28 (+3.91%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close7.16
Open7.17
Bid5.78 x 100
Ask7.45 x 100
Day's Range7.03 - 7.49
52 Week Range4.31 - 17.86
Volume2,159,345
Avg. Volume1,345,130
Market Cap468.82M
Beta1.07
PE Ratio (TTM)N/A
EPS (TTM)-1.83
Earnings DateFeb 19, 2018 - Feb 23, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.25
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Depomed Inc.
    Markit3 days ago

    See what the IHS Markit Score report has to say about Depomed Inc.

    Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.

  • Should You Buy Depomed Inc (NASDAQ:DEPO)?
    Simply Wall St.4 days ago

    Should You Buy Depomed Inc (NASDAQ:DEPO)?

    Depomed Inc (NASDAQ:DEPO), a pharmaceuticals company based in United States, saw significant share price volatility over the past couple of months on the NasdaqGS, rising to the highs of $8.67Read More...

  • TheStreet.com4 days ago

    Opioid Litigants Get Boost From Senate Report

    A report released by Missouri Sen. Claire McCaskill points to $10 million of payments flowing from a group of five opioid-producing companies to 15 patient advocacy groups over a five-year period.

  • Reuters5 days ago

    Opioid makers paid millions to advocacy groups -U.S. Senate report

    Five opioid manufacturers including OxyContin maker Purdue Pharma LP have paid more than $10 million to advocacy groups and doctors tied to them, many of whom amplified industry messages supporting the use of the painkillers, a U.S. Senate report said on Monday. The report, released by Democratic Senator Claire McCaskill, said groups who received the donations aligned themselves with industry goals and may have played a role in an epidemic that in 2016 led to 42,000 opioid overdose deaths. The report released by McCaskill, the U.S. Senate Homeland Security and Governmental Affairs Committee's ranking Democrat, said the groups issued guidance promoting opioids for chronic pain and lobbied against laws to curb their use.

  • See what the IHS Markit Score report has to say about Depomed Inc.
    Markit9 days ago

    See what the IHS Markit Score report has to say about Depomed Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • GlobeNewswire10 days ago

    Depomed to Present at Healthcare Conferences in February

    NEWARK, Calif., Feb. 07, 2018--. Depomed, Inc. today announced that members of senior management will participate in fireside chats at the following healthcare conferences during the month of February.. ...

  • A Look at Cara Therapeutics’ Intravenous CR845
    Market Realist16 days ago

    A Look at Cara Therapeutics’ Intravenous CR845

    What's in Store for Cara Therapeutics in 2018?

  • See what the IHS Markit Score report has to say about Depomed Inc.
    Markit17 days ago

    See what the IHS Markit Score report has to say about Depomed Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding DEPO totaled $248 million.

  • GlobeNewswirelast month

    Depomed Announces Closing of NUCYNTA Commercialization Agreement With Collegium Pharmaceutical

    NEWARK, Calif., Jan. 10, 2018-- Depomed, Inc. today announced the closing of its previously disclosed Commercialization Agreement for the U.S. rights to commercialize both NUCYNTA ® Extended Release and ...

  • An Intrinsic Value Calculation For Depomed Inc (NASDAQ:DEPO) Shows It’s 47.90% Undervalued
    Simply Wall St.last month

    An Intrinsic Value Calculation For Depomed Inc (NASDAQ:DEPO) Shows It’s 47.90% Undervalued

    How far off is Depomed Inc (NASDAQ:DEPO) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairlyRead More...

  • See what the IHS Markit Score report has to say about Depomed Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Depomed Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding DEPO totaled $1.92 billion.

  • Is Depomed Inc (NASDAQ:DEPO) A Financially Sound Company?
    Simply Wall St.2 months ago

    Is Depomed Inc (NASDAQ:DEPO) A Financially Sound Company?

    Depomed Inc (NASDAQ:DEPO) is a small-cap stock with a market capitalization of $541.29M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they endRead More...

  • Depomed Inc (NASDAQ:DEPO): Does -48.4% EPS Drop In A Year Reflect The Long-Term Trend?
    Simply Wall St.2 months ago

    Depomed Inc (NASDAQ:DEPO): Does -48.4% EPS Drop In A Year Reflect The Long-Term Trend?

    For investors with a long-term horizon, examining earnings trend over time and against industry peers is more insightful than looking at an earnings announcement in one point in time. InvestorsRead More...

  • See what the IHS Markit Score report has to say about Depomed Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Depomed Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Depomed Executes an Exit Strategy for Its Opioid Drug
    Motley Fool2 months ago

    Depomed Executes an Exit Strategy for Its Opioid Drug

    The company hopes a restructuring of its business can help it get back on its feet.

  • How Two Drugmakers Rocketed On A Deal That Sees One Exit Opioid Sales
    Investor's Business Daily2 months ago

    How Two Drugmakers Rocketed On A Deal That Sees One Exit Opioid Sales

    Collegium rocketed to a 22-month high Tuesday after striking a deal with Depomed to commercialize its painkiller Nucynta.

  • Here's Why Collegium Pharmaceutical Rose as Much as 23.5% Today
    Motley Fool2 months ago

    Here's Why Collegium Pharmaceutical Rose as Much as 23.5% Today

    The company is acquiring a new drug with over $200 million in annual sales, but it won't be cheap.

  • Barrons.com2 months ago

    Barron's After Hours: Collegium Jumps, Ascena Retail Slumps, Cleveland-Cliffs Falls

    The boost to U.S. stocks from tax-reform proved short-lived, with the Dow Jones Industrial Average finishing up less than 60 points, while the Nasdaq Composite and S&P 500 closed down 1.1% and 0.1%, respectively.  The negative momentum has spilled over into Asia-Pacific markets with benchmark indices in Australia, Japan and Korea all in the red on Tuesday morning. In U.S. after-hours stock news: Collegium Pharmaceutical (COLL) jumped 9% after announcing that it has entered into a definitive agreement with Depomed to commercialize Nucynta tablets in the U.S. Depomed (DEPO) jumped 4.9% on the same agreement. Ascena Retail Group (ASNA) slumped 20% after the fashion retailer posted a 50% year--on-year drop in FY18 first quarter earnings and offered weak guidance for the upcoming quarter.

  • American City Business Journals2 months ago

    Less than a year after hedge fund coup, East Bay drug maker cuts jobs, looks to move HQ

    A New York hedge fund that earlier this year flipped the board of Depomed Inc. and installed a new CEO to boost the company's value said Monday that it will cut 40 percent of its staff and move the drug company's headquarters out of California. The move is necessary, Depomed (DEPO) said in a Securities and Exchange Commission filing, because it is turning over sales of its best-selling pain drug, Nucynta, to Collegium Pharmaceutical Inc. and won't need as large of a workforce or as much space at its Newark headquarters. The Collegium deal, which the companies said is expected to close next month, means Depomed will receive royalties of at least $135 million a year for four years.

  • MarketWatch2 months ago

    Depomed farms out Nucynta sales, will lay off 40% of company

    DepoMed Inc. announced Monday afternoon that it will allow Collegium Pharmaceutical Inc. to handle sales of its most lucrative product, the Nucynta line of painkillers, and slash its workforce. DepoMed ...

  • GlobeNewswire2 months ago

    Depomed Announces NUCYNTA® Commercialization Agreement with Collegium Pharmaceutical

    -Transaction is Immediately Accretive and Improves 2018 EBITDA Outlook-. -Consistent with Stated Strategy of Maintaining a Strong NUCYNTA Franchise while Focusing on Neurology and Specialty Business Units-. ...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of DEPO earnings conference call or presentation 7-Nov-17 9:30pm GMT

    Q3 2017 Depomed Inc Earnings Call

  • See what the IHS Markit Score report has to say about Depomed Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Depomed Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.